Democritus University of Thrace (DUTH)
Οστεοπόρωση σε ασθενείς με τελικού σταδίου νεφρική ανεπάρκεια
Abstract
dc:descriptionBackground: End – Stage Renal Disease (ESRD) patients suffer from a range of skeletical abnormalities, described under the term of renal osteodystrophy. This term is a part of an overall systematic disturbance of bone metabolism in Chronic Renal Disease called Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD). On the other hand, low Bone Mineral Density (BMD) is a common finding in this group of patients. But the limits between renal bone disease and osteoporosis, as recognized in the general population, are very blurred. Osteoporosis refers to a disorder of bone metabolism, which affects mainly postmenopausal women and elderly patients, diagnosed by BMD measurement with dual-energy X-ray absorptiometry (DXA). Therefore it is obvious that in ESRD patients on standard hemodialysis program, renal osteodystrophy and osteoporosis present common pathogenic paths and have common spectrum of biochemical and istomorphopmetric disorders. Insufficient evidence-based infomation is available for the incidence and treatment of osteoporosis in hemodialysis (HD) patients. Aim: The aim of this study was to identify the incidence of low BMD in HD population and evaluate the effectiveness of certain therapeutic interventions. Methods: In 102 HD patients BMD was measured twice, 16+3 months apart, with DXA method at lumbar spine (LS) and femoral neck (FN). In the second measurement 66 of them presented a femoral neck (FN) t-score <-2,5. Of these 66 patients, 38 consented to a bone biopsy. Depending on both bone biopsy findings and parathyroid hormone levels, patients were assigned to treatment groups. Eleven patients with osteitis fibrosa and i-PTH >300pg/ml received cinacalcet, 11 with osteitis fibrosa and i-PTH <300pg/ml received ibandronate, 9 with adynamic bone disease received teriparatide and 7 with mild abnormalities received no treatment (control group). A third BMD measurement was done after an average treatment period of 13-16 months. We compared the annual percent change of FN and LS BMD before and during treatment. Results: FN and LS BMD decreased significantly in the cinacalcet group, with an annual change of 3.6 and 3.4% before treatment to -4,2% (p=0.04) and -7.7% (p=0.02) during treatment, respectively. In the teriparatide group, FN and LS BMD increased, although not significantly, with an annual change of -5.4 and -2.6% before treatment to 2.7 and 4.9% during treatment, respectively. In both the ibandronate and the control groups, BMD change rate remained negative during the whole study. Conclusions: Low BMD is prevalent in HD patients and may represent a great spectrum of underlying bone histology (both low and high bone turnover states). Teriparatide administration improved BMD in patients with adynamic bone disease, although these results did not reach statistical significance. In HD patients with osteitis fibrosa, ibadronate did not improve BMD while cinacalcet reduced BMD.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ginikopoulou, Evdoxia
- Γινικοπούλου, Ευδοξία
Subjects
dc:subject × 18- Χρόνια αιμοκάθαρση
- Οστική πυκνότητα
- Οστεοπόρωση
- Νεφρική οστεοδυστροφία
- Διφωσφονικά
- Καλσιομιμητικά
- Τεριπαρατίδη
- Chronic hemodialysis
- Bone mineral density
- Osteoporosis
- Renal osteodystrophy
- Biphosphonates
- Calcimimetics
- Teriparatide
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35127